Jane Street Group, LLC Blueprint Medicines Corp Put Options Transaction History

Jane Street Group, LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$84.1 - $120.5 $47.4 Million - $67.9 Million	563,400 New	563,400 $52.1 Million
Q1 2022 May 17, 2022	SELL	$54.1 - $110.08 $351,650 - $715,520	-6,500 Reduced 22.65%	22,200 $1.42 Million
Q4 2021 Feb 15, 2022	SELL	$94.25 - $115.99 $301,600 - $371,168	-3,200 Reduced 10.03%	28,700 $3.07 Million
Q3 2021 Nov 16, 2021	SELL	$80.98 - $109.47 $16,196 - $21,894	-200 Reduced 0.62%	31,900 $3.28 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $2.38 Million - $2.91 Million	28,800 Added 872.73%	32,100 $2.82 Million
Q1 2021 May 18, 2021	SELL	$90.71 - $108.28 $2.88 Million - $3.44 Million	-31,800 Reduced 90.6%	3,300 $321,000
Q4 2020 Feb 17, 2021	BUY	$92.08 - $124.48 $911,592 - $1.23 Million	9,900 Added 39.29%	35,100 $3.94 Million
Q3 2020 Nov 17, 2020	SELL	$66.45 - $92.7 $299,025 - $417,150	-4,500 Reduced 15.15%	25,200 $2.34 Million
Q2 2020 Aug 17, 2020	BUY	$57.09 - $79.27 $1.7 Million - $2.35 Million	29,700 New	29,700 $2.32 Million

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.57B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.